Partners Capital Investment Group LLP Has $2.65 Million Holdings in argenx SE (NASDAQ:ARGX)

Partners Capital Investment Group LLP decreased its holdings in argenx SE (NASDAQ:ARGX - Free Report) by 53.7% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 4,309 shares of the company's stock after selling 4,989 shares during the quarter. Partners Capital Investment Group LLP's holdings in argenx were worth $2,650,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also bought and sold shares of ARGX. Stifel Financial Corp grew its holdings in argenx by 15.3% during the 3rd quarter. Stifel Financial Corp now owns 8,832 shares of the company's stock worth $4,788,000 after acquiring an additional 1,170 shares during the last quarter. FMR LLC raised its holdings in argenx by 35.9% during the third quarter. FMR LLC now owns 4,793,472 shares of the company's stock worth $2,598,445,000 after buying an additional 1,265,486 shares during the last quarter. Simplify Asset Management Inc. raised its holdings in argenx by 64.0% during the third quarter. Simplify Asset Management Inc. now owns 2,419 shares of the company's stock worth $1,311,000 after buying an additional 944 shares during the last quarter. Ritholtz Wealth Management grew its stake in shares of argenx by 85.5% in the 4th quarter. Ritholtz Wealth Management now owns 898 shares of the company's stock worth $552,000 after acquiring an additional 414 shares in the last quarter. Finally, Westfield Capital Management Co. LP bought a new stake in shares of argenx in the 3rd quarter worth $571,000. Institutional investors and hedge funds own 60.32% of the company's stock.

Wall Street Analysts Forecast Growth

ARGX has been the subject of several recent research reports. JPMorgan Chase & Co. lifted their target price on shares of argenx from $640.00 to $670.00 and gave the stock an "overweight" rating in a research note on Monday, November 4th. William Blair raised shares of argenx from a "market perform" rating to an "outperform" rating in a research note on Friday, November 1st. Wells Fargo & Company lifted their price target on shares of argenx from $639.00 to $723.00 and gave the stock an "overweight" rating in a research note on Thursday, December 19th. Robert W. Baird lowered shares of argenx from an "outperform" rating to a "neutral" rating and increased their target price for the stock from $515.00 to $650.00 in a report on Friday, November 1st. Finally, Guggenheim lifted their price target on shares of argenx from $585.00 to $665.00 and gave the company a "buy" rating in a report on Friday, November 1st. One research analyst has rated the stock with a sell rating, two have given a hold rating, eighteen have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, argenx presently has a consensus rating of "Moderate Buy" and a consensus target price of $658.39.

argenx Stock Up 1.1 %

Shares of ARGX traded up $7.35 during trading on Thursday, reaching $647.49. The company's stock had a trading volume of 207,754 shares, compared to its average volume of 263,450. The company has a market cap of $39.34 billion, a price-to-earnings ratio of -735.78 and a beta of 0.58. The company has a fifty day moving average of $642.31 and a two-hundred day moving average of $585.45. argenx SE has a twelve month low of $349.86 and a twelve month high of $678.21.

argenx Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.